Increased choline levels coincide with enhanced proliferative activity of human neuroepithelial brain tumors

NMR in Biomedicine

Volumn 15, Issue 6, 2002, Pages 385-392

  Herminghaus, Sebastian ^a   Pilatus, Ulrich ^a   Möller Hartmann, Walter ^a   Raab, Peter ^a   Lanfermann, Heinrich ^a   Schlote, Wolfgang ^b   Zanella, Friedhelm E ^a  

^a GOETHE UNIVERSITY   (Germany)

^b Edinger Institute   (Germany)

Author keywords

Brain tumor; Ki 67 labeling index; Phospholipid metabolism; Proton MR spectroscopy

Indexed keywords

BRAIN; DERIVATIVES; HISTOLOGY; IMMUNOLOGY; NEUROLOGY; PHOSPHOLIPIDS; PHYSIOLOGY; SURGERY; TUMORS;

CELLULAR PROLIFERATION;

BIOMEDICAL ENGINEERING;

CHOLINE; KI 67 ANTIGEN; MEMBRANE PHOSPHOLIPID; PHOSPHOLIPID DERIVATIVE;

ADULT; ARTICLE; BRAIN TUMOR; CELL PROLIFERATION; CLINICAL TRIAL; CONCENTRATION RESPONSE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE MARKER; EARLY DIAGNOSIS; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPOTHESIS; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; MAJOR CLINICAL STUDY; MALE; MALIGNANT TRANSFORMATION; NEUROEPITHELIOMA; NON INVASIVE MEASUREMENT; PATIENT MONITORING; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; SECOND MESSENGER; TUMOR CLASSIFICATION; VOLUNTEER; WHITE MATTER; WORLD HEALTH ORGANIZATION;

BRAIN; BRAIN NEOPLASMS; CELL DIVISION; CHOLINE; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MIDDLE AGED; NEOPLASMS, NEUROEPITHELIAL; REFERENCE VALUES; REGRESSION ANALYSIS;

ILEX COOKII;

EID: 0036792374     PISSN: 09523480     EISSN: None     Source Type: Journal    
DOI: 10.1002/nbm.793     Document Type: Article

References (55)

1. Kleihues P, Burger PC, Scheithauer BW. Histological Typing of Tumors of the Central Nervous System. WHO Blue Book, 2nd edn. Springer: New York, 1993.
2. Gerdes J, Schwaab U, Lemke H, Stein H. Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation: Int. J. Cancer 1983; 31: 13-20.
3. Deckert M, Reifenberger G, Wechsler W. Determination of proliferative potential of human brain tumors using the monoclonal antibody Ki-67. J. Cancer Res. Oncol. 1989; 115: 179-188.
4. Ostertag CB, Volk B, Shibita T, Burger P, Kleihues P. The monoclonal antibody Ki-67 as a marker for proliferating cells in stereotactic biopsies of brain tumors. Acta Neurochir. (Wien) 1987; 89: 117-121.
5. Karamitopoulou E, Perents E, Diamantis I, Maraziotis T. Ki-67 immunoreactivity in human central nervous system brain tumors: a study with MIB.1 monoclonal antibody on archivial material. Acta Neuropathol. (Berlin) 1994; 87: 47-54.
6. Giangaspero F, Doglioni C, Rivano MT, Pileri S, Gerdes J, Stein H. Growth fraction in human brain tumors defined by the monoclonal antibody Ki-67. Acta Neuropathol. 1987; 74: 179-182.
7. Raghavan R, Steart PV, Weller RO. Cell proliferation patterns in the diagnosis of astrocytomas, anaplastic astrocytomas and glioblastoma multiforme: a Ki-67 study. Neuropathol. Appl. Neurobiol. 1990; 16: 123-133.
8. Sallinen PK, Haapasalo HK, Visakorpi T, Helen PT, Rantala IS, Isola JJ, Helin HJ. Prognostication of astrocytoma patient survival by Ki-67 (MIB-1), PCNA, and S-phase fraction using archival paraffin-embedded samples. J. Pathol. 1994; 174: 275-282.
9. Negendank W. Studies of human tumors by MRS: a review. NMR Biomed. 1992; 5: 303-324.
10. Podo F. Tumour phospholipid metabolism. NMR Biomed. 1999; 12: 413-439.
11. Usenius JP, Vainio P, Hernesniemi J, Kauppinen RA. Choline-containing compounds in human astrocytomas studied in vivo and in vitro. J. Neurochem. 1994; 63: 1538-1543.
12. Schiffer D. Prognosis and treatment of hemispheric astrocytomas. In Brain Tumors: Biology, Pathology and Clinical References, 2nd edn. Springer: New York, 1997; 150-155.
13. Schwechenheimer K. Spezielle Immunmorphologie neurogener Geschwülste. In Spezielle pathologische Anatomie, Vol. 13/IV, Doerr W, Seifert G (eds). Springer: Berlin, Tokyo, 1990.
14. Pierallini A, Bonamini M, Osti MF, Pantano P, Palmeggiani F, Santoro A, Maurizi Enrici R, Bozzao L. Supratentorial glioblastoma: neuroradiological findings and survival after surgery and radiotherapy. Neuroradiology, 1996; 38(Suppl. 1): 26-30.
15. Moonen CT, von Kienlin M, van Zijl PC, Cohen J, Gillen J, Daly P, Wolf G. Comparison of single-shot localization methods (STEAM and PRESS) for in vivo proton NMR spectroscopy. NMR Biomed. 1989; 2: 201-208.
16. 1H NMR chemical shift selective (CHESS) imaging. Phys. Med. Biol. 1985; 30: 341-344.
17. MRUI Home Page; www.mrui.uab.es/mrui/ [6 March 2002].
18. Van den Boogaart A, van Ormondt D, Pijnappel et al. Mathematics in Signal Processing III, McWhirter JG (ed.). Clarendon Press: Oxford, 1994; 175-195.
19. Van den Veen JW, de Beer PR, Luyten PR, van Ormondt D. Accurate quantification of in vivo 31P NMR signals using the Variable Projection Method and prior knowledge. Magn. Reson. Med. 1988; 6: 92-98.
20. Petroff OA, Spencer DD, Alger JR, Prichard JW. High field proton magnetic resonance spectroscopy of human cerebrum obtained during surgery for epilepsy. Neurology, 1989; 39: 1197-1202.
21. Michaelis T, Merboldt KD, Bruhn H, Hanicke W, Frahm J. Absolute concentrations of metabolites in the adult human brain in vivo: quantification of localized proton MR spectra. Radiology, 1993; 187: 219-227.
22. Schiffer D. Astrocytic tumors of the cerebral hemispheres. In Brain Tumors: Biology, Pathology and Clinical References, 2nd edn. Springer: Heidelberg, 1997; 139-224.
23. Kinoshita Y, Yokota A. Absolute concentrations of metabolites in human brain tumors using in vitro proton magnetic resonance spectroscopy. NMR Biomed. 1997; 10: 2-12.
24. Wilken B, Dechent P, Herms J, Maxton C, Markakis E, Hanefeld F, Frahm J. Quantitative proton magnetic resonance spectroscopy of focal brain lesions. Pediatr. Neurol. 2000; 23: 22-31.
25. Ruiz-Cabello J, Cohen JS. Phospholipid metabolism as indicators of cancer cell function. NMR Biomed. 1992; 5: 22.
26. 1H magnetic resonance spectroscopy in brain diseases. Brain Res. Brain Res. Rev. 2000; 33: 380-389.
27. Podo F, de Certaines JD. Magnetic resonance spectroscopy in cancer: phospholipid, neutral lipid and lipoprotein metabolism and function. Anticancer Res. 1996; 16: 1305-1315.
28. Ronen SM, Jackson LE, Beloueche M, Leach MO. Magnetic resonance detects changes in phosphocholine associated with Ras activation and inhibition in NIH 3T3 cells. Br. J. Cancer 2001; 84: 691-696.
29. Katz-Brull R, Degani H. Kinetics of choline transport and phosphorylation in human breast cancer cells; NMR application of the zero trans method. Anticancer Res. 1996; 16: 1375-1380.
30. Lacal JC, Moscat J, Aaronson SA. Novel source of 1,2-diacylglycerol elevated in cells transformed by Ha-ras oncogene. Nature 1987; 330: 269-272.
31. Podo F, Ferretti A, Knijn A, Zhang P, Ramoni C, Barletta B, Pini C, Baccarini S, Pulciani S. Detection of phosphatidylcholine-specific phospholipase C in NIH-3T3 fibroblasts and their H-ras transformants: NMR and immunochemical studies. Anticancer Res. 1996; 16: 1399-1412.
32. Ferretti A, Podo F, Carpinelli G, Chen L, Borghi P, Masella R. Detection of neutral active phosphatidylcholine-specific phospholipase C in Friend leukemia cells before and after erythroid differentiation. Anticancer Res. 1993; 13: 2309-2317.
33. Cook HW, Ridgway ND, Byers DM. Involvement of phospholipase D and protein kinase C in phorbol ester and fatty acid stimulated turnover of phosphatidylcholine and phosphatidylethanolamine in neural cells. Biochim. Biophys. Acta 1998; 1390: 103-117.
34. Cuadrado A, Carnero A, Dolfi F, Jimenez B, Lacal JC. Phosphorylcholine: a novel second messenger essential for mitogenic activity of growth factors. Oncogene 1993; 8: 2959-2968.
35. Shimizu H, Kumabe T, Shirane R, Yoshimoto T. Correlation between choline level measured by proton MR spectroscopy and Ki-67 labeling index in gliomas. Am. J. Neuroradiol. 2000; 21: 659-665.
36. Zuber P, Hamou MF, de Tribolet N. Identification of proliferating cells in human gliomas using the monoclonal antibody Ki-67. Neurosurgery 1988; 22: 364-368.
37. Jackowski S. Cell cycle regulation of membrane phospholipid metabolism. J. Biol. Chem. 1996; 271: 20219-20222.
38. Schröder R, Bien K, Kott R, Meyers I, Vossing R. The relationship between Ki-67 labeling and mitotic index in gliomas and meningeomas: demonstration of the variability of the intermitotic cycle time. Acta Neuropathol. (Berlin) 1991; 82: 389-394.
39. Brainard JA, Prayson RA, Barnett GH. Frozen section evaluation of stereotactic brain biopsies: diagnostic yield at the stereotactic target position in 188 cases. Arch Pathol. Lab. Med. 1997; 121: 481-484.
40. Rubinstein U. Immunohistochemical signspots-not markers-in neural tumor differentiation. Neuropathol. Appl. Neurobiol. 1986; 12: 523-537.
41. Shukla-Dave A, Gupta RK, Roy R, Husain N, Paul L, Venkatesh SK, Rashid MR, Chhabra DK, Husain M. Prospective evaluation of in vivo proton MR spectroscopy in differentiation of similar appearing intracranial cystic lesions. Magn. Reson. Imag. 2001; 19: 103-110.
42. Paulus W, Peiffer J. Intratumoral histologic heterogeneity of gliomas. A quantitative study. Cancer 1989; 64: 442-447.
43. . Miller BL, Chang L, Booth R, Ernst T, Cornford M, Nikas D, McBride D, Jenden DJ. In vivo 1H MRS choline: correlation with in vitro chemistry/histology. Life Sci. 1996; 58: 1929-1935.
44. Bhakoo KK, Williams SR, Florian CL, Land H, Noble MD. Immortalization and transformation are associated with specific alterations in choline metabolism. Cancer Res. 1996; 56: 4630-4635.
45. 1H NMR spectroscopy in vivo and in vitro. J. Comput. Assist. Tomogr. 1994; 18: 705-713.
46. Manton DJ, Lowry M, Blackband SJ, Horsman A. Determination of proton metabolite concentrations and relaxation parameters in normal human brain and intracranial tumours. NMR Biomed. 1995; 8: 104-112.
47. Tedeschi G, Lundbom N, Raman R, Bonavita S, Duyn JH, Alger JR, Di Chiro G. Increased choline signal coinciding with malignant degeneration of cerebral gliomas: a serial proton magnetic resonance spectroscopy imaging study. J. Neurosurg. 1997; 87: 516-524.
48. Graves EE, Nelson SJ, Vigneron DB, Verhey L, McDermott M, Larson D, Chang S, Prados MD, Dillon WP. Serial proton MR spectroscopic imaging of recurrent malignant gliomas after gamma knife radiosurgery. Am. J. Neuroradiol. 2001; 22: 613-624.
49. Moller-Hartmann W, Herminghaus S, Krings T, Marquardt G, Lanfermann H, Pilatus U, Zanella FE. Clinical application of proton magnetic resonance spectroscopy in the diagnosis of intracranial mass lesions. Neuroradiology 2002; 44: 371-381.
50. 1H magnetic resonance spectroscopy for the discrimination of primary brain tumors. Invest. Radiol. 1999; 34: 230-235.
51. Bell JD, Bhakoo KK. Metabolic changes underlying 31P MR spectral alterations in human hepatic tumours. NMR Biomed. 1998; 11: 354-359.
52. Bluml S, Seymour KJ, Ross BD. Developmental changes in choline- and ethanolamine-containing compounds measured with proton-decoupled (31)P MRS in in vivo human brain. Magn. Reson. Med. 1999; 42: 643-654.
53. Lin AP, Bluml S, Seymour KJ, Tan JP, Rand R, Ross BD. Quantitative proton-decoupled 31P MRS of human brain tumors. 7th Annual Meeting of the International Society of Magnetic Resonance in Medicine, 1999; 1394.
54. Ting YL, Sherr D, Degani H. Variations in energy and phospholipid metabolism in normal and cancer human mammary epithelial cells. Anticancer Res. 1996; 16: 1381-1388.
55. Aiken NR, Gillies RJ. Phosphomonoester metabolism as a function of cell proliferative status and exogenous precursors. Anticancer Res. 1996; 16: 1393-1397.